Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma | Zendy

Hassel Jessica C. | Zendy; Amann Philipp M. | Zendy; Schadendorf Dirk | Zendy; Eichmüller Stefan B. | Zendy; Nagler Markus | Zendy; Bazhin Alexandr V. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Lecithin retinol acyltransferase as a potential prognostic marker for malignant melanoma

Author(s) -

Hassel Jessica C.,

Amann Philipp M.,

Schadendorf Dirk,

Eichmüller Stefan B.,

Nagler Markus,

Bazhin Alexandr V.

Publication year - 2013

Publication title -

experimental dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.108

H-Index - 96

eISSN - 1600-0625

pISSN - 0906-6705

DOI - 10.1111/exd.12236

Subject(s) - melanoma , rpe65 , acyltransferase , immunohistochemistry , medicine , cancer research , oncology , pathology , biology , enzyme , retinal , biochemistry , retinal pigment epithelium , ophthalmology

Metabolism inside cells differs between cancer and normal cells. Because disturbance of vitamin A metabolism might be important, we investigated expression of the enzymes lecithin retinol acyltransferase ( LRAT ) and RPE 65 by immunohistochemistry in melanoma metastases and melanocytic nevi. Semiquantitative evaluation of this expression revealed downregulated expression of RPE 65 in malignant melanoma compared with benign melanocytic nevi ( P < 0.001). In contrast, expression of LRAT was not significantly different ( P = 0.339). High LRAT expression in melanoma metastases was inversely correlated with patient survival; Kaplan–Meier analysis revealed earlier melanoma‐related death ( P = 0.003). Expression of LRAT might, therefore, be a prognostic marker of the clinical course of melanoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research